Development of fluorescence-labeled antibody for immune checkpoint inhibitor using engineered probiotics

AMB Express

Original Article

Natsumi Nomura¹  Fu Namai¹  Takashi Sato¹  Shunsuke Sumiya¹  Takeshi Shimosato¹ 

[1]Department of Biomolecular Innovation, Institute for Biomedical Sciences, Shinshu University, 8304 Minamiminowa, Kamiina, 399-4598, Nagano, Japan

关键词: gmLAB;    Next-generation probiotics;    PD-L1;    scFv;    Tumor microenvironment;   

DOI  :  10.1186/s13568-023-01509-y

 received in 2022-11-22, accepted in 2023-01-08,  发布年份 2023

来源: Springer

【 摘 要 】

Here, we developed a genetically modified lactic acid bacteria (gmLAB) that produces green fluorescent protein (GFP)-conjugating, anti-programmed death-ligand 1 (PD-L1) single-chain variable fragments (scFv) for use as an anti-cancer device that targets immune checkpoint molecules. Since PD-L1 plays a key role as an immune checkpoint molecule in the tumor microenvironment, inhibition and detection of PD-L1 are important in cancer research. The anti-PD-L1 scFv was designed based on atezolizumab, a humanized IgG1 monoclonal antibody, and integrated into a lactococcal GFP gene expression vector. Gene expression from the constructed gmLAB was confirmed by western blotting and GFP fluorescence. The ability of GFP-conjugating anti-PD-L1 scFv against the target antigen, PD-L1 protein, was shown using an enzyme-linked immunosorbent assay. Finally, the ability to recognize PD-L1-expressing tumor-cell lines was confirmed using flow cytometry and fluorescence microscopy. Our results suggest that the gmLAB could be applied to in vivo imaging in cancer as an affordable diagnostic/treatment tool.Graphical Abstract

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 5

41116_2022_35_Article_IEq649.gif

41116_2022_35_Article_IEq645.gif

41116_2022_35_Article_IEq621.gif

41116_2022_35_Article_IEq595.gif

41116_2022_35_Article_IEq587.gif